glp-1 receptor agonist atrial fibrillation risk Glucagon-like peptide 1 agonists: cardiovascular benefits and mechanisms of action Effects of Glucagon-Like Peptide-1 Receptor

Exendin-4 inhibits the remodeling in the remote myocardium of rats following acute MI by attenuating -catenin activation and activating glycogen synthase kinase-3, -arrestin-2 and protein phosphatase 2A [12]

10.1093/eurheartj/ehae508 88

Yki-Jrvinen H

Taylor SI, Blau JE, Rother KI, Beitelshees AL (2019) SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: balancing benefits and risks

At 24 weeks, least-squares mean changes from baseline in HbA1c with retatrutide were 0.43% for the 0.5 mg group, 1.39% for the 4 mg escalation group, 1.30% for the 4 mg group, 1.99% for the 8 mg slow escalation group, 1.88% for the 8 mg fast escalation group, and 2.02% for the 12 mg escalation group, versus 0.01% for the placebo group and 1.41% for the 1.5 mg dulaglutide group